Anticancer Drugs Durvalumab Oncology Pharmacology Physiotherapy

Durvalumab (Dosage Modifications)

In this article we will discuss Durvalumab (Dosage Modifications)

In this article, we will discuss Durvalumab (Dosage Modifications). So, let’s get started.

No dose reduction for Durvalumab is recommended. In general, withhold Durvalumab for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue Durvalumab for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require
systemic immunosuppressive treatment, or an inability to reduce corticosteroid dose to 10 mg or less of prednisone or equivalent per day within 12 weeks of initiating corticosteroids.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.